| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/20/2015 | US8936803 Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof |
| 01/20/2015 | US8936800 Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
| 01/20/2015 | US8936784 Absorbable in situ gel-forming system, method of making and use thereof |
| 01/20/2015 | US8936780 Stimuli responsive polyester amide particles |
| 01/20/2015 | CA2798368C Composition for preventing or treating osteoporosis and manufacturing method therefor |
| 01/20/2015 | CA2798239C Malodor neutralizing compositions comprising undecylenic acid or citric acid |
| 01/20/2015 | CA2788236C Substituted pyrrolidine-2-carboxamides |
| 01/20/2015 | CA2771775C Compounds and compositions as protein kinase inhibitors |
| 01/20/2015 | CA2761845C Thiophene[3,4-c]pyrrole pde4 mediators |
| 01/20/2015 | CA2757574C Inhibitors of bacterial type iii secretion system |
| 01/20/2015 | CA2742993C Pyrazine compounds as phosphodiesterase 10 inhibitors |
| 01/20/2015 | CA2741096C Triterpenoid 2-deoxy glycosides, method of preparation thereof and use thereof as medicaments |
| 01/20/2015 | CA2673444C Polymorphs of a mglur5 receptor antagonist |
| 01/20/2015 | CA2666658C Chymase inhibitors |
| 01/20/2015 | CA2664052C An improved process for the preparation of temozolomide and analogs |
| 01/20/2015 | CA2659662C Concentrated methotrexate solutions |
| 01/20/2015 | CA2648898C Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| 01/20/2015 | CA2630468C Medicinal drug |
| 01/20/2015 | CA2618240C Sustained-release formulations of topiramate |
| 01/20/2015 | CA2616451C Substituted benzyl derivatives as gsk-3 inhibitors |
| 01/20/2015 | CA2615678C Isotopically substituted pantoprazole |
| 01/20/2015 | CA2615670C Isotopically substituted proton pump inhibitors |
| 01/20/2015 | CA2614711C Liquid formulation based on a guanidinoacetic acid component |
| 01/20/2015 | CA2607207C Biphenyl and naphthyl-phenyl hydroxamic acid derivatives |
| 01/20/2015 | CA2575002C Hiv inhibiting 1,2,4-triazin-6-one derivatives |
| 01/20/2015 | CA2568241C Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| 01/20/2015 | CA2539575C Method of removing transition metals, especially from metathesis reaction products |
| 01/20/2015 | CA2494132C Pharmaceutical composition, metered dose dispenser containing same, and use of pharmaceutical composition and metered dose dispenser in administering pharmaceutical agent to oral membranes |
| 01/20/2015 | CA2441893C Method of attenuating reactions to skin irritants |
| 01/15/2015 | WO2015006752A1 Combination therapies for malaria |
| 01/15/2015 | WO2015006735A1 Nanoparticles and methods of producing the same |
| 01/15/2015 | WO2015006733A1 Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
| 01/15/2015 | WO2015006731A1 Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
| 01/15/2015 | WO2015006715A1 Dehydroleucodine derivatives and uses thereof |
| 01/15/2015 | WO2015006708A1 Treating elevated levels of eosinophils and/or basophils |
| 01/15/2015 | WO2015006691A1 Pro-drug forming compounds |
| 01/15/2015 | WO2015006689A1 Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| 01/15/2015 | WO2015006685A1 Promotion of smoking cessation |
| 01/15/2015 | WO2015006651A1 Compositions comprising hydroxytyrosol, resveratrol, lycopene, flavanols, and/or flavonoids and use thereof |
| 01/15/2015 | WO2015006646A1 Compositions comprising hydroxytyrosol, curcumin, and/or astaxanthin and use thereof |
| 01/15/2015 | WO2015006615A1 Anticancer agents |
| 01/15/2015 | WO2015006592A1 N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| 01/15/2015 | WO2015006591A1 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| 01/15/2015 | WO2015006546A1 Cell collection device and method |
| 01/15/2015 | WO2015006535A2 Dictyostatin prodrugs and methods of their use |
| 01/15/2015 | WO2015006520A1 Ido inhibitors |
| 01/15/2015 | WO2015006508A2 Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14 |
| 01/15/2015 | WO2015006492A1 Kinase inhibitors for the treatment of disease |
| 01/15/2015 | WO2015006465A1 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same |
| 01/15/2015 | WO2015006460A1 Compositions of hyaluronan with high elasticity and uses thereof |
| 01/15/2015 | WO2015006355A2 Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| 01/15/2015 | WO2015006319A1 Treatment of papulopustular rosacea with ivermectin |
| 01/15/2015 | WO2015006318A2 Ocular composition and kits thereof |
| 01/15/2015 | WO2015006315A1 Dihydroxyphenyl neurotransmitter compounds, compositions and methods |
| 01/15/2015 | WO2015006305A1 Treatment of inflammatory lesions of rosacea with ivermectin |
| 01/15/2015 | WO2015006299A1 Pharmaceutical formulations of tranexamic acid and their use |
| 01/15/2015 | WO2015006287A2 Compositions prepared from poultry and methods of their use |
| 01/15/2015 | WO2015006280A1 Fused piperidine amides as modulators of ion channels |
| 01/15/2015 | WO2015006193A1 Tricyclic heterocycles as bet protein inhibitors |
| 01/15/2015 | WO2015006181A1 Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
| 01/15/2015 | WO2015006177A1 Formulations for cathepsin k inhibitors with vitamin d |
| 01/15/2015 | WO2015006100A1 Aryl amide kinase inhibitors |
| 01/15/2015 | WO2015005985A1 Topical treatment of localized scleroderma |
| 01/15/2015 | WO2015005901A1 Combinations of hepatitis c virus inhibitors |
| 01/15/2015 | WO2015005816A1 Preparation for treating and preventing bovine postpartum endometritis |
| 01/15/2015 | WO2015005723A1 Cell-penetrating peptide and conjugate comprising same |
| 01/15/2015 | WO2015005670A1 LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME |
| 01/15/2015 | WO2015005669A1 LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME |
| 01/15/2015 | WO2015005630A1 Composition capable of inhibiting tslp secretion and alleviating allergic diseases |
| 01/15/2015 | WO2015005615A1 Method for preparation of benzimidazole derivatives |
| 01/15/2015 | WO2015005603A1 Small molecule, indirubin-3-oxime, for prevention and treatment of bone disease |
| 01/15/2015 | WO2015005562A1 Therapeutic agent for neurological disorders including, as active ingredients, anthocyanin and gabab receptor agonist |
| 01/15/2015 | WO2015005512A1 Composition for antioxidation or skin whitening containing 21-o-angeloyltheasapogenol e3 ingredient derived from green tea seed |
| 01/15/2015 | WO2015005511A1 Antiaging skin preparation composition containing 21-o-angeloyltheasapogenol e3 ingredient derived from green tea seed |
| 01/15/2015 | WO2015005491A1 Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease |
| 01/15/2015 | WO2015005489A1 Heterocyclic compound |
| 01/15/2015 | WO2015005468A1 P2x4 receptor antagonist |
| 01/15/2015 | WO2015005467A1 P2x4 receptor antagonist |
| 01/15/2015 | WO2015005466A1 Method for producing lipid having high eicosapentaenoic acid content |
| 01/15/2015 | WO2015005459A1 Pharmaceutical composition for respiratory administration |
| 01/15/2015 | WO2015005458A1 Glycosaminoglycan derivative and method for producing same |
| 01/15/2015 | WO2015005443A1 Oral composition |
| 01/15/2015 | WO2015005429A1 Novel pde4 inhibitor |
| 01/15/2015 | WO2015005393A1 Prophylactic or therapeutic agent for aortic aneurysm and packaged food or drink |
| 01/15/2015 | WO2015005365A1 Drug for treatment of nonalcoholic fatty liver disease |
| 01/15/2015 | WO2015005345A1 Core-shell crosslinked hyaluronic acid gel particles, production method for same, and medical material |
| 01/15/2015 | WO2015005305A1 Alxr agonist compound |
| 01/15/2015 | WO2015005301A1 GELIDIUM AMANSII EXTRACT CONTAINING PGF2α |
| 01/15/2015 | WO2015005253A1 Novel lipid |
| 01/15/2015 | WO2015005248A1 Drug for treating/preventing allergic respiratory tract inflammation |
| 01/15/2015 | WO2015005060A1 Method for producing ellagic acid composition |
| 01/15/2015 | WO2015004636A1 A pharmaceutical combination for the treatment of melanoma |
| 01/15/2015 | WO2015004634A2 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain |
| 01/15/2015 | WO2015004618A1 Enhancer of zeste homolog 2 inhibitors |
| 01/15/2015 | WO2015004617A1 Extended-release pharmaceutical compositions of metoprolol |
| 01/15/2015 | WO2015004610A1 1,5-dihydropyrrol-2-one derivatives as inhibitors of p53-mdm2/mdm4 protein-protein interaction |
| 01/15/2015 | WO2015004505A1 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain |
| 01/15/2015 | WO2015004485A1 Therapeutic compounds |
| 01/15/2015 | WO2015004481A1 Imidazo-condensed bicycles as inhibitors of discoidin domain receptors (ddrs) |
| 01/15/2015 | WO2015004475A2 Compositions and methods |